Global Non-prescription Drugs Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
A medication (also referred to as medicine, pharmaceutical drug, or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
LPI (LP Information)' newest research report, the “Non-prescription Drugs Industry Forecast” looks at past sales and reviews total world Non-prescription Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Non-prescription Drugs sales for 2023 through 2029. With Non-prescription Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-prescription Drugs industry.
This Insight Report provides a comprehensive analysis of the global Non-prescription Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-prescription Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Non-prescription Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-prescription Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-prescription Drugs.
The global Non-prescription Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Non-prescription Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Non-prescription Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Non-prescription Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Non-prescription Drugs players cover Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD), Novartis, AbbVie, Gilead Sciences and GlaxoSmithKline (GSK), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-prescription Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Non-prescription Drugs market?
What factors are driving Non-prescription Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non-prescription Drugs market opportunities vary by end market size?
How does Non-prescription Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
A medication (also referred to as medicine, pharmaceutical drug, or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
LPI (LP Information)' newest research report, the “Non-prescription Drugs Industry Forecast” looks at past sales and reviews total world Non-prescription Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Non-prescription Drugs sales for 2023 through 2029. With Non-prescription Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-prescription Drugs industry.
This Insight Report provides a comprehensive analysis of the global Non-prescription Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-prescription Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Non-prescription Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-prescription Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-prescription Drugs.
The global Non-prescription Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Non-prescription Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Non-prescription Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Non-prescription Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Non-prescription Drugs players cover Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD), Novartis, AbbVie, Gilead Sciences and GlaxoSmithKline (GSK), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-prescription Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Brand Drugs
- Generic Drug
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Roche
- Sanofi
- Johnson & Johnson
- Merck & Co. (MSD)
- Novartis
- AbbVie
- Gilead Sciences
- GlaxoSmithKline (GSK)
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- Teva
- Bayer
- Novo Nordisk
- Allergan
- Takeda
- Boehringer Ingelheim
- Takeda
What is the 10-year outlook for the global Non-prescription Drugs market?
What factors are driving Non-prescription Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non-prescription Drugs market opportunities vary by end market size?
How does Non-prescription Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-prescription Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Non-prescription Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Non-prescription Drugs by Country/Region, 2018, 2022 & 2029
2.2 Non-prescription Drugs Segment by Type
2.2.1 Brand Drugs
2.2.2 Generic Drug
2.3 Non-prescription Drugs Sales by Type
2.3.1 Global Non-prescription Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Non-prescription Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Non-prescription Drugs Sale Price by Type (2018-2023)
2.4 Non-prescription Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Non-prescription Drugs Sales by Application
2.5.1 Global Non-prescription Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Non-prescription Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Non-prescription Drugs Sale Price by Application (2018-2023)
3 GLOBAL NON-PRESCRIPTION DRUGS BY COMPANY
3.1 Global Non-prescription Drugs Breakdown Data by Company
3.1.1 Global Non-prescription Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Non-prescription Drugs Sales Market Share by Company (2018-2023)
3.2 Global Non-prescription Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Non-prescription Drugs Revenue by Company (2018-2023)
3.2.2 Global Non-prescription Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Non-prescription Drugs Sale Price by Company
3.4 Key Manufacturers Non-prescription Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-prescription Drugs Product Location Distribution
3.4.2 Players Non-prescription Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NON-PRESCRIPTION DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Non-prescription Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Non-prescription Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Non-prescription Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Non-prescription Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Non-prescription Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Non-prescription Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Non-prescription Drugs Sales Growth
4.4 APAC Non-prescription Drugs Sales Growth
4.5 Europe Non-prescription Drugs Sales Growth
4.6 Middle East & Africa Non-prescription Drugs Sales Growth
5 AMERICAS
5.1 Americas Non-prescription Drugs Sales by Country
5.1.1 Americas Non-prescription Drugs Sales by Country (2018-2023)
5.1.2 Americas Non-prescription Drugs Revenue by Country (2018-2023)
5.2 Americas Non-prescription Drugs Sales by Type
5.3 Americas Non-prescription Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-prescription Drugs Sales by Region
6.1.1 APAC Non-prescription Drugs Sales by Region (2018-2023)
6.1.2 APAC Non-prescription Drugs Revenue by Region (2018-2023)
6.2 APAC Non-prescription Drugs Sales by Type
6.3 APAC Non-prescription Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-prescription Drugs by Country
7.1.1 Europe Non-prescription Drugs Sales by Country (2018-2023)
7.1.2 Europe Non-prescription Drugs Revenue by Country (2018-2023)
7.2 Europe Non-prescription Drugs Sales by Type
7.3 Europe Non-prescription Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-prescription Drugs by Country
8.1.1 Middle East & Africa Non-prescription Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Non-prescription Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Non-prescription Drugs Sales by Type
8.3 Middle East & Africa Non-prescription Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-prescription Drugs
10.3 Manufacturing Process Analysis of Non-prescription Drugs
10.4 Industry Chain Structure of Non-prescription Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-prescription Drugs Distributors
11.3 Non-prescription Drugs Customer
12 WORLD FORECAST REVIEW FOR NON-PRESCRIPTION DRUGS BY GEOGRAPHIC REGION
12.1 Global Non-prescription Drugs Market Size Forecast by Region
12.1.1 Global Non-prescription Drugs Forecast by Region (2024-2029)
12.1.2 Global Non-prescription Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Non-prescription Drugs Forecast by Type
12.7 Global Non-prescription Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Non-prescription Drugs Product Portfolios and Specifications
13.1.3 Pfizer Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche Non-prescription Drugs Product Portfolios and Specifications
13.2.3 Roche Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Non-prescription Drugs Product Portfolios and Specifications
13.3.3 Sanofi Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Information
13.4.2 Johnson & Johnson Non-prescription Drugs Product Portfolios and Specifications
13.4.3 Johnson & Johnson Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Johnson & Johnson Main Business Overview
13.4.5 Johnson & Johnson Latest Developments
13.5 Merck & Co. (MSD)
13.5.1 Merck & Co. (MSD) Company Information
13.5.2 Merck & Co. (MSD) Non-prescription Drugs Product Portfolios and Specifications
13.5.3 Merck & Co. (MSD) Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merck & Co. (MSD) Main Business Overview
13.5.5 Merck & Co. (MSD) Latest Developments
13.6 Novartis
13.6.1 Novartis Company Information
13.6.2 Novartis Non-prescription Drugs Product Portfolios and Specifications
13.6.3 Novartis Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Novartis Main Business Overview
13.6.5 Novartis Latest Developments
13.7 AbbVie
13.7.1 AbbVie Company Information
13.7.2 AbbVie Non-prescription Drugs Product Portfolios and Specifications
13.7.3 AbbVie Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 AbbVie Main Business Overview
13.7.5 AbbVie Latest Developments
13.8 Gilead Sciences
13.8.1 Gilead Sciences Company Information
13.8.2 Gilead Sciences Non-prescription Drugs Product Portfolios and Specifications
13.8.3 Gilead Sciences Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Gilead Sciences Main Business Overview
13.8.5 Gilead Sciences Latest Developments
13.9 GlaxoSmithKline (GSK)
13.9.1 GlaxoSmithKline (GSK) Company Information
13.9.2 GlaxoSmithKline (GSK) Non-prescription Drugs Product Portfolios and Specifications
13.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 GlaxoSmithKline (GSK) Main Business Overview
13.9.5 GlaxoSmithKline (GSK) Latest Developments
13.10 Amgen
13.10.1 Amgen Company Information
13.10.2 Amgen Non-prescription Drugs Product Portfolios and Specifications
13.10.3 Amgen Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Amgen Main Business Overview
13.10.5 Amgen Latest Developments
13.11 AstraZeneca
13.11.1 AstraZeneca Company Information
13.11.2 AstraZeneca Non-prescription Drugs Product Portfolios and Specifications
13.11.3 AstraZeneca Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 AstraZeneca Main Business Overview
13.11.5 AstraZeneca Latest Developments
13.12 Bristol-Myers Squibb
13.12.1 Bristol-Myers Squibb Company Information
13.12.2 Bristol-Myers Squibb Non-prescription Drugs Product Portfolios and Specifications
13.12.3 Bristol-Myers Squibb Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Bristol-Myers Squibb Main Business Overview
13.12.5 Bristol-Myers Squibb Latest Developments
13.13 Eli Lilly
13.13.1 Eli Lilly Company Information
13.13.2 Eli Lilly Non-prescription Drugs Product Portfolios and Specifications
13.13.3 Eli Lilly Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Eli Lilly Main Business Overview
13.13.5 Eli Lilly Latest Developments
13.14 Teva
13.14.1 Teva Company Information
13.14.2 Teva Non-prescription Drugs Product Portfolios and Specifications
13.14.3 Teva Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Teva Main Business Overview
13.14.5 Teva Latest Developments
13.15 Bayer
13.15.1 Bayer Company Information
13.15.2 Bayer Non-prescription Drugs Product Portfolios and Specifications
13.15.3 Bayer Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Bayer Main Business Overview
13.15.5 Bayer Latest Developments
13.16 Novo Nordisk
13.16.1 Novo Nordisk Company Information
13.16.2 Novo Nordisk Non-prescription Drugs Product Portfolios and Specifications
13.16.3 Novo Nordisk Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Novo Nordisk Main Business Overview
13.16.5 Novo Nordisk Latest Developments
13.17 Allergan
13.17.1 Allergan Company Information
13.17.2 Allergan Non-prescription Drugs Product Portfolios and Specifications
13.17.3 Allergan Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Allergan Main Business Overview
13.17.5 Allergan Latest Developments
13.18 Takeda
13.18.1 Takeda Company Information
13.18.2 Takeda Non-prescription Drugs Product Portfolios and Specifications
13.18.3 Takeda Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Takeda Main Business Overview
13.18.5 Takeda Latest Developments
13.19 Boehringer Ingelheim
13.19.1 Boehringer Ingelheim Company Information
13.19.2 Boehringer Ingelheim Non-prescription Drugs Product Portfolios and Specifications
13.19.3 Boehringer Ingelheim Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Boehringer Ingelheim Main Business Overview
13.19.5 Boehringer Ingelheim Latest Developments
13.20 Takeda
13.20.1 Takeda Company Information
13.20.2 Takeda Non-prescription Drugs Product Portfolios and Specifications
13.20.3 Takeda Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Takeda Main Business Overview
13.20.5 Takeda Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-prescription Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Non-prescription Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Non-prescription Drugs by Country/Region, 2018, 2022 & 2029
2.2 Non-prescription Drugs Segment by Type
2.2.1 Brand Drugs
2.2.2 Generic Drug
2.3 Non-prescription Drugs Sales by Type
2.3.1 Global Non-prescription Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Non-prescription Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Non-prescription Drugs Sale Price by Type (2018-2023)
2.4 Non-prescription Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Non-prescription Drugs Sales by Application
2.5.1 Global Non-prescription Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Non-prescription Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Non-prescription Drugs Sale Price by Application (2018-2023)
3 GLOBAL NON-PRESCRIPTION DRUGS BY COMPANY
3.1 Global Non-prescription Drugs Breakdown Data by Company
3.1.1 Global Non-prescription Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Non-prescription Drugs Sales Market Share by Company (2018-2023)
3.2 Global Non-prescription Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Non-prescription Drugs Revenue by Company (2018-2023)
3.2.2 Global Non-prescription Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Non-prescription Drugs Sale Price by Company
3.4 Key Manufacturers Non-prescription Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-prescription Drugs Product Location Distribution
3.4.2 Players Non-prescription Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NON-PRESCRIPTION DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Non-prescription Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Non-prescription Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Non-prescription Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Non-prescription Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Non-prescription Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Non-prescription Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Non-prescription Drugs Sales Growth
4.4 APAC Non-prescription Drugs Sales Growth
4.5 Europe Non-prescription Drugs Sales Growth
4.6 Middle East & Africa Non-prescription Drugs Sales Growth
5 AMERICAS
5.1 Americas Non-prescription Drugs Sales by Country
5.1.1 Americas Non-prescription Drugs Sales by Country (2018-2023)
5.1.2 Americas Non-prescription Drugs Revenue by Country (2018-2023)
5.2 Americas Non-prescription Drugs Sales by Type
5.3 Americas Non-prescription Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-prescription Drugs Sales by Region
6.1.1 APAC Non-prescription Drugs Sales by Region (2018-2023)
6.1.2 APAC Non-prescription Drugs Revenue by Region (2018-2023)
6.2 APAC Non-prescription Drugs Sales by Type
6.3 APAC Non-prescription Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-prescription Drugs by Country
7.1.1 Europe Non-prescription Drugs Sales by Country (2018-2023)
7.1.2 Europe Non-prescription Drugs Revenue by Country (2018-2023)
7.2 Europe Non-prescription Drugs Sales by Type
7.3 Europe Non-prescription Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-prescription Drugs by Country
8.1.1 Middle East & Africa Non-prescription Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Non-prescription Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Non-prescription Drugs Sales by Type
8.3 Middle East & Africa Non-prescription Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-prescription Drugs
10.3 Manufacturing Process Analysis of Non-prescription Drugs
10.4 Industry Chain Structure of Non-prescription Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-prescription Drugs Distributors
11.3 Non-prescription Drugs Customer
12 WORLD FORECAST REVIEW FOR NON-PRESCRIPTION DRUGS BY GEOGRAPHIC REGION
12.1 Global Non-prescription Drugs Market Size Forecast by Region
12.1.1 Global Non-prescription Drugs Forecast by Region (2024-2029)
12.1.2 Global Non-prescription Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Non-prescription Drugs Forecast by Type
12.7 Global Non-prescription Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Non-prescription Drugs Product Portfolios and Specifications
13.1.3 Pfizer Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche Non-prescription Drugs Product Portfolios and Specifications
13.2.3 Roche Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Non-prescription Drugs Product Portfolios and Specifications
13.3.3 Sanofi Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Information
13.4.2 Johnson & Johnson Non-prescription Drugs Product Portfolios and Specifications
13.4.3 Johnson & Johnson Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Johnson & Johnson Main Business Overview
13.4.5 Johnson & Johnson Latest Developments
13.5 Merck & Co. (MSD)
13.5.1 Merck & Co. (MSD) Company Information
13.5.2 Merck & Co. (MSD) Non-prescription Drugs Product Portfolios and Specifications
13.5.3 Merck & Co. (MSD) Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merck & Co. (MSD) Main Business Overview
13.5.5 Merck & Co. (MSD) Latest Developments
13.6 Novartis
13.6.1 Novartis Company Information
13.6.2 Novartis Non-prescription Drugs Product Portfolios and Specifications
13.6.3 Novartis Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Novartis Main Business Overview
13.6.5 Novartis Latest Developments
13.7 AbbVie
13.7.1 AbbVie Company Information
13.7.2 AbbVie Non-prescription Drugs Product Portfolios and Specifications
13.7.3 AbbVie Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 AbbVie Main Business Overview
13.7.5 AbbVie Latest Developments
13.8 Gilead Sciences
13.8.1 Gilead Sciences Company Information
13.8.2 Gilead Sciences Non-prescription Drugs Product Portfolios and Specifications
13.8.3 Gilead Sciences Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Gilead Sciences Main Business Overview
13.8.5 Gilead Sciences Latest Developments
13.9 GlaxoSmithKline (GSK)
13.9.1 GlaxoSmithKline (GSK) Company Information
13.9.2 GlaxoSmithKline (GSK) Non-prescription Drugs Product Portfolios and Specifications
13.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 GlaxoSmithKline (GSK) Main Business Overview
13.9.5 GlaxoSmithKline (GSK) Latest Developments
13.10 Amgen
13.10.1 Amgen Company Information
13.10.2 Amgen Non-prescription Drugs Product Portfolios and Specifications
13.10.3 Amgen Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Amgen Main Business Overview
13.10.5 Amgen Latest Developments
13.11 AstraZeneca
13.11.1 AstraZeneca Company Information
13.11.2 AstraZeneca Non-prescription Drugs Product Portfolios and Specifications
13.11.3 AstraZeneca Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 AstraZeneca Main Business Overview
13.11.5 AstraZeneca Latest Developments
13.12 Bristol-Myers Squibb
13.12.1 Bristol-Myers Squibb Company Information
13.12.2 Bristol-Myers Squibb Non-prescription Drugs Product Portfolios and Specifications
13.12.3 Bristol-Myers Squibb Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Bristol-Myers Squibb Main Business Overview
13.12.5 Bristol-Myers Squibb Latest Developments
13.13 Eli Lilly
13.13.1 Eli Lilly Company Information
13.13.2 Eli Lilly Non-prescription Drugs Product Portfolios and Specifications
13.13.3 Eli Lilly Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Eli Lilly Main Business Overview
13.13.5 Eli Lilly Latest Developments
13.14 Teva
13.14.1 Teva Company Information
13.14.2 Teva Non-prescription Drugs Product Portfolios and Specifications
13.14.3 Teva Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Teva Main Business Overview
13.14.5 Teva Latest Developments
13.15 Bayer
13.15.1 Bayer Company Information
13.15.2 Bayer Non-prescription Drugs Product Portfolios and Specifications
13.15.3 Bayer Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Bayer Main Business Overview
13.15.5 Bayer Latest Developments
13.16 Novo Nordisk
13.16.1 Novo Nordisk Company Information
13.16.2 Novo Nordisk Non-prescription Drugs Product Portfolios and Specifications
13.16.3 Novo Nordisk Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Novo Nordisk Main Business Overview
13.16.5 Novo Nordisk Latest Developments
13.17 Allergan
13.17.1 Allergan Company Information
13.17.2 Allergan Non-prescription Drugs Product Portfolios and Specifications
13.17.3 Allergan Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Allergan Main Business Overview
13.17.5 Allergan Latest Developments
13.18 Takeda
13.18.1 Takeda Company Information
13.18.2 Takeda Non-prescription Drugs Product Portfolios and Specifications
13.18.3 Takeda Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Takeda Main Business Overview
13.18.5 Takeda Latest Developments
13.19 Boehringer Ingelheim
13.19.1 Boehringer Ingelheim Company Information
13.19.2 Boehringer Ingelheim Non-prescription Drugs Product Portfolios and Specifications
13.19.3 Boehringer Ingelheim Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Boehringer Ingelheim Main Business Overview
13.19.5 Boehringer Ingelheim Latest Developments
13.20 Takeda
13.20.1 Takeda Company Information
13.20.2 Takeda Non-prescription Drugs Product Portfolios and Specifications
13.20.3 Takeda Non-prescription Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Takeda Main Business Overview
13.20.5 Takeda Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Non-prescription Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Non-prescription Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Brand Drugs
Table 4. Major Players of Generic Drug
Table 5. Global Non-prescription Drugs Sales by Type (2018-2023) & (K Units)
Table 6. Global Non-prescription Drugs Sales Market Share by Type (2018-2023)
Table 7. Global Non-prescription Drugs Revenue by Type (2018-2023) & ($ million)
Table 8. Global Non-prescription Drugs Revenue Market Share by Type (2018-2023)
Table 9. Global Non-prescription Drugs Sale Price by Type (2018-2023) & (USD/Unit)
Table 10. Global Non-prescription Drugs Sales by Application (2018-2023) & (K Units)
Table 11. Global Non-prescription Drugs Sales Market Share by Application (2018-2023)
Table 12. Global Non-prescription Drugs Revenue by Application (2018-2023)
Table 13. Global Non-prescription Drugs Revenue Market Share by Application (2018-2023)
Table 14. Global Non-prescription Drugs Sale Price by Application (2018-2023) & (USD/Unit)
Table 15. Global Non-prescription Drugs Sales by Company (2018-2023) & (K Units)
Table 16. Global Non-prescription Drugs Sales Market Share by Company (2018-2023)
Table 17. Global Non-prescription Drugs Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Non-prescription Drugs Revenue Market Share by Company (2018-2023)
Table 19. Global Non-prescription Drugs Sale Price by Company (2018-2023) & (USD/Unit)
Table 20. Key Manufacturers Non-prescription Drugs Producing Area Distribution and Sales Area
Table 21. Players Non-prescription Drugs Products Offered
Table 22. Non-prescription Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Non-prescription Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Non-prescription Drugs Sales Market Share Geographic Region (2018-2023)
Table 27. Global Non-prescription Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Non-prescription Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Non-prescription Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Non-prescription Drugs Sales Market Share by Country/Region (2018-2023)
Table 31. Global Non-prescription Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Non-prescription Drugs Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Non-prescription Drugs Sales by Country (2018-2023) & (K Units)
Table 34. Americas Non-prescription Drugs Sales Market Share by Country (2018-2023)
Table 35. Americas Non-prescription Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Non-prescription Drugs Revenue Market Share by Country (2018-2023)
Table 37. Americas Non-prescription Drugs Sales by Type (2018-2023) & (K Units)
Table 38. Americas Non-prescription Drugs Sales by Application (2018-2023) & (K Units)
Table 39. APAC Non-prescription Drugs Sales by Region (2018-2023) & (K Units)
Table 40. APAC Non-prescription Drugs Sales Market Share by Region (2018-2023)
Table 41. APAC Non-prescription Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Non-prescription Drugs Revenue Market Share by Region (2018-2023)
Table 43. APAC Non-prescription Drugs Sales by Type (2018-2023) & (K Units)
Table 44. APAC Non-prescription Drugs Sales by Application (2018-2023) & (K Units)
Table 45. Europe Non-prescription Drugs Sales by Country (2018-2023) & (K Units)
Table 46. Europe Non-prescription Drugs Sales Market Share by Country (2018-2023)
Table 47. Europe Non-prescription Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Non-prescription Drugs Revenue Market Share by Country (2018-2023)
Table 49. Europe Non-prescription Drugs Sales by Type (2018-2023) & (K Units)
Table 50. Europe Non-prescription Drugs Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Non-prescription Drugs Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Non-prescription Drugs Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Non-prescription Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Non-prescription Drugs Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Non-prescription Drugs Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Non-prescription Drugs Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Non-prescription Drugs
Table 58. Key Market Challenges & Risks of Non-prescription Drugs
Table 59. Key Industry Trends of Non-prescription Drugs
Table 60. Non-prescription Drugs Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Non-prescription Drugs Distributors List
Table 63. Non-prescription Drugs Customer List
Table 64. Global Non-prescription Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Non-prescription Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Non-prescription Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Non-prescription Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Non-prescription Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Non-prescription Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Non-prescription Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Non-prescription Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Non-prescription Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Non-prescription Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Non-prescription Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Non-prescription Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Non-prescription Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Non-prescription Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Pfizer Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer Non-prescription Drugs Product Portfolios and Specifications
Table 80. Pfizer Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Roche Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Roche Non-prescription Drugs Product Portfolios and Specifications
Table 85. Roche Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 86. Roche Main Business
Table 87. Roche Latest Developments
Table 88. Sanofi Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Non-prescription Drugs Product Portfolios and Specifications
Table 90. Sanofi Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. Johnson & Johnson Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Johnson & Johnson Non-prescription Drugs Product Portfolios and Specifications
Table 95. Johnson & Johnson Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 96. Johnson & Johnson Main Business
Table 97. Johnson & Johnson Latest Developments
Table 98. Merck & Co. (MSD) Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Merck & Co. (MSD) Non-prescription Drugs Product Portfolios and Specifications
Table 100. Merck & Co. (MSD) Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 101. Merck & Co. (MSD) Main Business
Table 102. Merck & Co. (MSD) Latest Developments
Table 103. Novartis Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Novartis Non-prescription Drugs Product Portfolios and Specifications
Table 105. Novartis Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 106. Novartis Main Business
Table 107. Novartis Latest Developments
Table 108. AbbVie Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. AbbVie Non-prescription Drugs Product Portfolios and Specifications
Table 110. AbbVie Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 111. AbbVie Main Business
Table 112. AbbVie Latest Developments
Table 113. Gilead Sciences Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Gilead Sciences Non-prescription Drugs Product Portfolios and Specifications
Table 115. Gilead Sciences Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 116. Gilead Sciences Main Business
Table 117. Gilead Sciences Latest Developments
Table 118. GlaxoSmithKline (GSK) Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. GlaxoSmithKline (GSK) Non-prescription Drugs Product Portfolios and Specifications
Table 120. GlaxoSmithKline (GSK) Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 121. GlaxoSmithKline (GSK) Main Business
Table 122. GlaxoSmithKline (GSK) Latest Developments
Table 123. Amgen Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Amgen Non-prescription Drugs Product Portfolios and Specifications
Table 125. Amgen Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 126. Amgen Main Business
Table 127. Amgen Latest Developments
Table 128. AstraZeneca Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. AstraZeneca Non-prescription Drugs Product Portfolios and Specifications
Table 130. AstraZeneca Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 131. AstraZeneca Main Business
Table 132. AstraZeneca Latest Developments
Table 133. Bristol-Myers Squibb Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Bristol-Myers Squibb Non-prescription Drugs Product Portfolios and Specifications
Table 135. Bristol-Myers Squibb Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 136. Bristol-Myers Squibb Main Business
Table 137. Bristol-Myers Squibb Latest Developments
Table 138. Eli Lilly Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Eli Lilly Non-prescription Drugs Product Portfolios and Specifications
Table 140. Eli Lilly Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 141. Eli Lilly Main Business
Table 142. Eli Lilly Latest Developments
Table 143. Teva Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Teva Non-prescription Drugs Product Portfolios and Specifications
Table 145. Teva Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 146. Teva Main Business
Table 147. Teva Latest Developments
Table 148. Bayer Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149. Bayer Non-prescription Drugs Product Portfolios and Specifications
Table 150. Bayer Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 151. Bayer Main Business
Table 152. Bayer Latest Developments
Table 153. Novo Nordisk Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. Novo Nordisk Non-prescription Drugs Product Portfolios and Specifications
Table 155. Novo Nordisk Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 156. Novo Nordisk Main Business
Table 157. Novo Nordisk Latest Developments
Table 158. Allergan Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. Allergan Non-prescription Drugs Product Portfolios and Specifications
Table 160. Allergan Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 161. Allergan Main Business
Table 162. Allergan Latest Developments
Table 163. Takeda Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. Takeda Non-prescription Drugs Product Portfolios and Specifications
Table 165. Takeda Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 166. Takeda Main Business
Table 167. Takeda Latest Developments
Table 168. Boehringer Ingelheim Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 169. Boehringer Ingelheim Non-prescription Drugs Product Portfolios and Specifications
Table 170. Boehringer Ingelheim Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 171. Boehringer Ingelheim Main Business
Table 172. Boehringer Ingelheim Latest Developments
Table 173. Takeda Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 174. Takeda Non-prescription Drugs Product Portfolios and Specifications
Table 175. Takeda Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 176. Takeda Main Business
Table 177. Takeda Latest Developments
Table 1. Non-prescription Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Non-prescription Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Brand Drugs
Table 4. Major Players of Generic Drug
Table 5. Global Non-prescription Drugs Sales by Type (2018-2023) & (K Units)
Table 6. Global Non-prescription Drugs Sales Market Share by Type (2018-2023)
Table 7. Global Non-prescription Drugs Revenue by Type (2018-2023) & ($ million)
Table 8. Global Non-prescription Drugs Revenue Market Share by Type (2018-2023)
Table 9. Global Non-prescription Drugs Sale Price by Type (2018-2023) & (USD/Unit)
Table 10. Global Non-prescription Drugs Sales by Application (2018-2023) & (K Units)
Table 11. Global Non-prescription Drugs Sales Market Share by Application (2018-2023)
Table 12. Global Non-prescription Drugs Revenue by Application (2018-2023)
Table 13. Global Non-prescription Drugs Revenue Market Share by Application (2018-2023)
Table 14. Global Non-prescription Drugs Sale Price by Application (2018-2023) & (USD/Unit)
Table 15. Global Non-prescription Drugs Sales by Company (2018-2023) & (K Units)
Table 16. Global Non-prescription Drugs Sales Market Share by Company (2018-2023)
Table 17. Global Non-prescription Drugs Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Non-prescription Drugs Revenue Market Share by Company (2018-2023)
Table 19. Global Non-prescription Drugs Sale Price by Company (2018-2023) & (USD/Unit)
Table 20. Key Manufacturers Non-prescription Drugs Producing Area Distribution and Sales Area
Table 21. Players Non-prescription Drugs Products Offered
Table 22. Non-prescription Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Non-prescription Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Non-prescription Drugs Sales Market Share Geographic Region (2018-2023)
Table 27. Global Non-prescription Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Non-prescription Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Non-prescription Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Non-prescription Drugs Sales Market Share by Country/Region (2018-2023)
Table 31. Global Non-prescription Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Non-prescription Drugs Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Non-prescription Drugs Sales by Country (2018-2023) & (K Units)
Table 34. Americas Non-prescription Drugs Sales Market Share by Country (2018-2023)
Table 35. Americas Non-prescription Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Non-prescription Drugs Revenue Market Share by Country (2018-2023)
Table 37. Americas Non-prescription Drugs Sales by Type (2018-2023) & (K Units)
Table 38. Americas Non-prescription Drugs Sales by Application (2018-2023) & (K Units)
Table 39. APAC Non-prescription Drugs Sales by Region (2018-2023) & (K Units)
Table 40. APAC Non-prescription Drugs Sales Market Share by Region (2018-2023)
Table 41. APAC Non-prescription Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Non-prescription Drugs Revenue Market Share by Region (2018-2023)
Table 43. APAC Non-prescription Drugs Sales by Type (2018-2023) & (K Units)
Table 44. APAC Non-prescription Drugs Sales by Application (2018-2023) & (K Units)
Table 45. Europe Non-prescription Drugs Sales by Country (2018-2023) & (K Units)
Table 46. Europe Non-prescription Drugs Sales Market Share by Country (2018-2023)
Table 47. Europe Non-prescription Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Non-prescription Drugs Revenue Market Share by Country (2018-2023)
Table 49. Europe Non-prescription Drugs Sales by Type (2018-2023) & (K Units)
Table 50. Europe Non-prescription Drugs Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Non-prescription Drugs Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Non-prescription Drugs Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Non-prescription Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Non-prescription Drugs Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Non-prescription Drugs Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Non-prescription Drugs Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Non-prescription Drugs
Table 58. Key Market Challenges & Risks of Non-prescription Drugs
Table 59. Key Industry Trends of Non-prescription Drugs
Table 60. Non-prescription Drugs Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Non-prescription Drugs Distributors List
Table 63. Non-prescription Drugs Customer List
Table 64. Global Non-prescription Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Non-prescription Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Non-prescription Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Non-prescription Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Non-prescription Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Non-prescription Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Non-prescription Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Non-prescription Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Non-prescription Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Non-prescription Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Non-prescription Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Non-prescription Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Non-prescription Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Non-prescription Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Pfizer Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer Non-prescription Drugs Product Portfolios and Specifications
Table 80. Pfizer Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Roche Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Roche Non-prescription Drugs Product Portfolios and Specifications
Table 85. Roche Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 86. Roche Main Business
Table 87. Roche Latest Developments
Table 88. Sanofi Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Non-prescription Drugs Product Portfolios and Specifications
Table 90. Sanofi Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. Johnson & Johnson Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Johnson & Johnson Non-prescription Drugs Product Portfolios and Specifications
Table 95. Johnson & Johnson Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 96. Johnson & Johnson Main Business
Table 97. Johnson & Johnson Latest Developments
Table 98. Merck & Co. (MSD) Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Merck & Co. (MSD) Non-prescription Drugs Product Portfolios and Specifications
Table 100. Merck & Co. (MSD) Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 101. Merck & Co. (MSD) Main Business
Table 102. Merck & Co. (MSD) Latest Developments
Table 103. Novartis Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Novartis Non-prescription Drugs Product Portfolios and Specifications
Table 105. Novartis Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 106. Novartis Main Business
Table 107. Novartis Latest Developments
Table 108. AbbVie Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. AbbVie Non-prescription Drugs Product Portfolios and Specifications
Table 110. AbbVie Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 111. AbbVie Main Business
Table 112. AbbVie Latest Developments
Table 113. Gilead Sciences Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Gilead Sciences Non-prescription Drugs Product Portfolios and Specifications
Table 115. Gilead Sciences Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 116. Gilead Sciences Main Business
Table 117. Gilead Sciences Latest Developments
Table 118. GlaxoSmithKline (GSK) Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. GlaxoSmithKline (GSK) Non-prescription Drugs Product Portfolios and Specifications
Table 120. GlaxoSmithKline (GSK) Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 121. GlaxoSmithKline (GSK) Main Business
Table 122. GlaxoSmithKline (GSK) Latest Developments
Table 123. Amgen Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Amgen Non-prescription Drugs Product Portfolios and Specifications
Table 125. Amgen Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 126. Amgen Main Business
Table 127. Amgen Latest Developments
Table 128. AstraZeneca Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. AstraZeneca Non-prescription Drugs Product Portfolios and Specifications
Table 130. AstraZeneca Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 131. AstraZeneca Main Business
Table 132. AstraZeneca Latest Developments
Table 133. Bristol-Myers Squibb Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Bristol-Myers Squibb Non-prescription Drugs Product Portfolios and Specifications
Table 135. Bristol-Myers Squibb Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 136. Bristol-Myers Squibb Main Business
Table 137. Bristol-Myers Squibb Latest Developments
Table 138. Eli Lilly Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Eli Lilly Non-prescription Drugs Product Portfolios and Specifications
Table 140. Eli Lilly Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 141. Eli Lilly Main Business
Table 142. Eli Lilly Latest Developments
Table 143. Teva Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Teva Non-prescription Drugs Product Portfolios and Specifications
Table 145. Teva Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 146. Teva Main Business
Table 147. Teva Latest Developments
Table 148. Bayer Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149. Bayer Non-prescription Drugs Product Portfolios and Specifications
Table 150. Bayer Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 151. Bayer Main Business
Table 152. Bayer Latest Developments
Table 153. Novo Nordisk Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. Novo Nordisk Non-prescription Drugs Product Portfolios and Specifications
Table 155. Novo Nordisk Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 156. Novo Nordisk Main Business
Table 157. Novo Nordisk Latest Developments
Table 158. Allergan Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. Allergan Non-prescription Drugs Product Portfolios and Specifications
Table 160. Allergan Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 161. Allergan Main Business
Table 162. Allergan Latest Developments
Table 163. Takeda Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. Takeda Non-prescription Drugs Product Portfolios and Specifications
Table 165. Takeda Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 166. Takeda Main Business
Table 167. Takeda Latest Developments
Table 168. Boehringer Ingelheim Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 169. Boehringer Ingelheim Non-prescription Drugs Product Portfolios and Specifications
Table 170. Boehringer Ingelheim Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 171. Boehringer Ingelheim Main Business
Table 172. Boehringer Ingelheim Latest Developments
Table 173. Takeda Basic Information, Non-prescription Drugs Manufacturing Base, Sales Area and Its Competitors
Table 174. Takeda Non-prescription Drugs Product Portfolios and Specifications
Table 175. Takeda Non-prescription Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 176. Takeda Main Business
Table 177. Takeda Latest Developments
LIST OF FIGURES
Figure 1. Picture of Non-prescription Drugs
Figure 2. Non-prescription Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-prescription Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Non-prescription Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Non-prescription Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Brand Drugs
Figure 10. Product Picture of Generic Drug
Figure 11. Global Non-prescription Drugs Sales Market Share by Type in 2022
Figure 12. Global Non-prescription Drugs Revenue Market Share by Type (2018-2023)
Figure 13. Non-prescription Drugs Consumed in Hospital
Figure 14. Global Non-prescription Drugs Market: Hospital (2018-2023) & (K Units)
Figure 15. Non-prescription Drugs Consumed in Clinic
Figure 16. Global Non-prescription Drugs Market: Clinic (2018-2023) & (K Units)
Figure 17. Non-prescription Drugs Consumed in Other
Figure 18. Global Non-prescription Drugs Market: Other (2018-2023) & (K Units)
Figure 19. Global Non-prescription Drugs Sales Market Share by Application (2022)
Figure 20. Global Non-prescription Drugs Revenue Market Share by Application in 2022
Figure 21. Non-prescription Drugs Sales Market by Company in 2022 (K Units)
Figure 22. Global Non-prescription Drugs Sales Market Share by Company in 2022
Figure 23. Non-prescription Drugs Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Non-prescription Drugs Revenue Market Share by Company in 2022
Figure 25. Global Non-prescription Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Non-prescription Drugs Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Non-prescription Drugs Sales 2018-2023 (K Units)
Figure 28. Americas Non-prescription Drugs Revenue 2018-2023 ($ Millions)
Figure 29. APAC Non-prescription Drugs Sales 2018-2023 (K Units)
Figure 30. APAC Non-prescription Drugs Revenue 2018-2023 ($ Millions)
Figure 31. Europe Non-prescription Drugs Sales 2018-2023 (K Units)
Figure 32. Europe Non-prescription Drugs Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Non-prescription Drugs Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Non-prescription Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Americas Non-prescription Drugs Sales Market Share by Country in 2022
Figure 36. Americas Non-prescription Drugs Revenue Market Share by Country in 2022
Figure 37. Americas Non-prescription Drugs Sales Market Share by Type (2018-2023)
Figure 38. Americas Non-prescription Drugs Sales Market Share by Application (2018-2023)
Figure 39. United States Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Non-prescription Drugs Sales Market Share by Region in 2022
Figure 44. APAC Non-prescription Drugs Revenue Market Share by Regions in 2022
Figure 45. APAC Non-prescription Drugs Sales Market Share by Type (2018-2023)
Figure 46. APAC Non-prescription Drugs Sales Market Share by Application (2018-2023)
Figure 47. China Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Non-prescription Drugs Sales Market Share by Country in 2022
Figure 55. Europe Non-prescription Drugs Revenue Market Share by Country in 2022
Figure 56. Europe Non-prescription Drugs Sales Market Share by Type (2018-2023)
Figure 57. Europe Non-prescription Drugs Sales Market Share by Application (2018-2023)
Figure 58. Germany Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Non-prescription Drugs Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Non-prescription Drugs Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Non-prescription Drugs Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Non-prescription Drugs Sales Market Share by Application (2018-2023)
Figure 67. Egypt Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Non-prescription Drugs in 2022
Figure 73. Manufacturing Process Analysis of Non-prescription Drugs
Figure 74. Industry Chain Structure of Non-prescription Drugs
Figure 75. Channels of Distribution
Figure 76. Global Non-prescription Drugs Sales Market Forecast by Region (2024-2029)
Figure 77. Global Non-prescription Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Non-prescription Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Non-prescription Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Non-prescription Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Non-prescription Drugs Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Non-prescription Drugs
Figure 2. Non-prescription Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-prescription Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Non-prescription Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Non-prescription Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Brand Drugs
Figure 10. Product Picture of Generic Drug
Figure 11. Global Non-prescription Drugs Sales Market Share by Type in 2022
Figure 12. Global Non-prescription Drugs Revenue Market Share by Type (2018-2023)
Figure 13. Non-prescription Drugs Consumed in Hospital
Figure 14. Global Non-prescription Drugs Market: Hospital (2018-2023) & (K Units)
Figure 15. Non-prescription Drugs Consumed in Clinic
Figure 16. Global Non-prescription Drugs Market: Clinic (2018-2023) & (K Units)
Figure 17. Non-prescription Drugs Consumed in Other
Figure 18. Global Non-prescription Drugs Market: Other (2018-2023) & (K Units)
Figure 19. Global Non-prescription Drugs Sales Market Share by Application (2022)
Figure 20. Global Non-prescription Drugs Revenue Market Share by Application in 2022
Figure 21. Non-prescription Drugs Sales Market by Company in 2022 (K Units)
Figure 22. Global Non-prescription Drugs Sales Market Share by Company in 2022
Figure 23. Non-prescription Drugs Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Non-prescription Drugs Revenue Market Share by Company in 2022
Figure 25. Global Non-prescription Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Non-prescription Drugs Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Non-prescription Drugs Sales 2018-2023 (K Units)
Figure 28. Americas Non-prescription Drugs Revenue 2018-2023 ($ Millions)
Figure 29. APAC Non-prescription Drugs Sales 2018-2023 (K Units)
Figure 30. APAC Non-prescription Drugs Revenue 2018-2023 ($ Millions)
Figure 31. Europe Non-prescription Drugs Sales 2018-2023 (K Units)
Figure 32. Europe Non-prescription Drugs Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Non-prescription Drugs Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Non-prescription Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Americas Non-prescription Drugs Sales Market Share by Country in 2022
Figure 36. Americas Non-prescription Drugs Revenue Market Share by Country in 2022
Figure 37. Americas Non-prescription Drugs Sales Market Share by Type (2018-2023)
Figure 38. Americas Non-prescription Drugs Sales Market Share by Application (2018-2023)
Figure 39. United States Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Non-prescription Drugs Sales Market Share by Region in 2022
Figure 44. APAC Non-prescription Drugs Revenue Market Share by Regions in 2022
Figure 45. APAC Non-prescription Drugs Sales Market Share by Type (2018-2023)
Figure 46. APAC Non-prescription Drugs Sales Market Share by Application (2018-2023)
Figure 47. China Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Non-prescription Drugs Sales Market Share by Country in 2022
Figure 55. Europe Non-prescription Drugs Revenue Market Share by Country in 2022
Figure 56. Europe Non-prescription Drugs Sales Market Share by Type (2018-2023)
Figure 57. Europe Non-prescription Drugs Sales Market Share by Application (2018-2023)
Figure 58. Germany Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Non-prescription Drugs Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Non-prescription Drugs Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Non-prescription Drugs Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Non-prescription Drugs Sales Market Share by Application (2018-2023)
Figure 67. Egypt Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Non-prescription Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Non-prescription Drugs in 2022
Figure 73. Manufacturing Process Analysis of Non-prescription Drugs
Figure 74. Industry Chain Structure of Non-prescription Drugs
Figure 75. Channels of Distribution
Figure 76. Global Non-prescription Drugs Sales Market Forecast by Region (2024-2029)
Figure 77. Global Non-prescription Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Non-prescription Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Non-prescription Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Non-prescription Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Non-prescription Drugs Revenue Market Share Forecast by Application (2024-2029)
